Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Shi

Showing results (461-470 of 546) with videos related to

Pageof 55
Sort By:
European Journal of Heart Failure|August 26, 2020
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HFSenthil Selvaraj, Brian L Claggett, Marc A Pfeffer, et al.
Plos One|December 23, 2009
Neuropeptide Y knockout mice reveal a central role of NPY in the coordination of bone mass to body weightPaul A Baldock, Nicola J Lee, Frank Driessler, et al.
JACC. Heart Failure|April 4, 2020
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection FractionJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|July 1, 2017
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF TrialScott D Solomon, Adel R Rizkala, Jianjian Gong, et al.
The Review of Scientific Instruments|February 2, 2010
A laser-Compton scattering prototype experiment at 100 MeV linac of Shanghai Institute of Applied PhysicsW Luo, W Xu, Q Y Pan, et al.
Journal of Internal Medicine|May 7, 2020
Tumour biomarkers: association with heart failure outcomesC Shi, H H van der Wal, H H W Silljé, et al.
JACC. Heart Failure|July 15, 2019
Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF TrialAlvin Chandra, Muthiah Vaduganathan, Eldrin F Lewis, et al.
Zhonghua Yi Xue Za Zhi|July 24, 2023
[Survey of <i>Helicobacter pylori</i> levofloxacin and clarithromycin resistance rates and drug resistance genes in Ningxia, 2020-2022]L M Du, S J Hu, X M Chen, et al.
European Heart Journal|June 30, 2016
Geographic variations in the PARADIGM-HF heart failure trialSøren Lund Kristensen, Felipe Martinez, Pardeep S Jhund, et al.
Zhonghua Yi Xue Za Zhi|May 13, 2020
[On-pump total arterial revascularization in coronary artery disease patients with left ventricular dysfunction: a multi-center retrospective study]D X Liu, X J Chen, B S Zheng, et al.
Pageof 55

Showing results (461-470 of 546) with videos related to

Sort By:
Pageof 55
European Journal of Heart Failure|August 26, 2020
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HFSenthil Selvaraj, Brian L Claggett, Marc A Pfeffer, et al.
Plos One|December 23, 2009
Neuropeptide Y knockout mice reveal a central role of NPY in the coordination of bone mass to body weightPaul A Baldock, Nicola J Lee, Frank Driessler, et al.
JACC. Heart Failure|April 4, 2020
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection FractionJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|July 1, 2017
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF TrialScott D Solomon, Adel R Rizkala, Jianjian Gong, et al.
The Review of Scientific Instruments|February 2, 2010
A laser-Compton scattering prototype experiment at 100 MeV linac of Shanghai Institute of Applied PhysicsW Luo, W Xu, Q Y Pan, et al.
Journal of Internal Medicine|May 7, 2020
Tumour biomarkers: association with heart failure outcomesC Shi, H H van der Wal, H H W Silljé, et al.
JACC. Heart Failure|July 15, 2019
Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF TrialAlvin Chandra, Muthiah Vaduganathan, Eldrin F Lewis, et al.
Zhonghua Yi Xue Za Zhi|July 24, 2023
[Survey of <i>Helicobacter pylori</i> levofloxacin and clarithromycin resistance rates and drug resistance genes in Ningxia, 2020-2022]L M Du, S J Hu, X M Chen, et al.
European Heart Journal|June 30, 2016
Geographic variations in the PARADIGM-HF heart failure trialSøren Lund Kristensen, Felipe Martinez, Pardeep S Jhund, et al.
Zhonghua Yi Xue Za Zhi|May 13, 2020
[On-pump total arterial revascularization in coronary artery disease patients with left ventricular dysfunction: a multi-center retrospective study]D X Liu, X J Chen, B S Zheng, et al.
Pageof 55